Trials / Completed
CompletedNCT04476017
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)
An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Supernus Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 50 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this two-part study was to evaluate the safety and tolerability of SAGE-718 and its effects on cognitive, neuropsychiatric, and motor symptoms in participants with Parkinson's disease mild cognitive impairment (PD-MCI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SAGE-718 | Oral tablets. |
Timeline
- Start date
- 2020-07-31
- Primary completion
- 2022-03-25
- Completion
- 2022-03-25
- First posted
- 2020-07-17
- Last updated
- 2025-09-15
- Results posted
- 2023-06-06
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04476017. Inclusion in this directory is not an endorsement.